Third Point Files 13D on Strata Critical Medical, Urges Strategic Alternatives Including a Sale
SRTA is trading near its 52-week low of $3.95 (9.9% above the low).
Summary
Third Point disclosed a 5.8% activist stake in Strata Critical Medical and publicly urged the company to explore strategic alternatives, including a potential sale. The filing upgrades a prior passive 13G position into an activist 13D.
Key Events · Ownership and Investor Activity · SRTA
-
Third Point Files Activist 13D
Third Point LLC and Daniel S. Loeb reported beneficial ownership of 5,126,511 shares, or 5.8% of the class, upgrading from a Schedule 13G previously filed 2025-08-11 and amended 2025-11-14.
-
Public Push for a Sale
Third Point stated the stock is undervalued, that the business is not of a scale to support its current overhead, that management incentive options are not aligned with shareholder value, and that the Issuer should explore strategic alternatives including a potential sale managed by an investment bank.
-
Cost Basis and Continued Buying
The position cost $24,452,374 in aggregate (about $4.77 per share). Third Point added 58,743 shares on 10/12/2026 at $4.55 and 67,768 shares on 10/13/2026 at $4.53, roughly $574,000 of fresh buying.
-
No Sale Process Announced
The filing states Third Point's view that a strategic review should occur; it does not state that the Issuer has begun one or agreed to any transaction.
Analysis · SRTA · Industrial Applications And Services
Third Point LLC and Daniel S. Loeb disclosed a 5.8% stake (5,126,511 shares, $24.45M cost basis) and, more importantly, went public with an activist thesis: the stock is undervalued, the business is too small to support its current overhead, management's incentive options are misaligned, and the company should explore strategic alternatives including a sale run by an investment bank. This is a first-time 13D filing, upgraded from a passive 13G, which converts a quiet holder into an activist pushing for a sale — a change that can reprice the stock on its own. Third Point kept buying into weakness, adding 126,511 shares on 10/12 and 10/13 at $4.55 and $4.53, below the $4.77 average cost of the position and below today's $4.34 quote. The filing does not state that a sale process has begun; it states Third Point's belief that one should.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.4% of the 908 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRTA was trading at $4.34 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $383.9M. The 52-week trading range was $3.95 to $6.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.